540 related articles for article (PubMed ID: 17076227)
1. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
Ter Arkh; 2006; 78(9):61-71. PubMed ID: 17076227
[TBL] [Abstract][Full Text] [Related]
2. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
Ter Arkh; 2006; 78(8):14-20. PubMed ID: 17078211
[TBL] [Abstract][Full Text] [Related]
3. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
[TBL] [Abstract][Full Text] [Related]
4. [Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study].
Skvortsov AA; Nasonova SN; Sychev AV; Orlova IaA; Baklanova NA; Masenko VP; Mareev VIu; Belenkov IuN
Kardiologiia; 2006; 46(7):33-51. PubMed ID: 16883264
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy].
Skvortsov AA; Mareev VY; Chelmakina SM; Baklanova NA; Belenkov IuN
Kardiologiia; 2007; 47(10):12-23. PubMed ID: 18260939
[TBL] [Abstract][Full Text] [Related]
6. [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].
Skvortsov AA; Mareev VIu; Orlova IaA; Chelmakina SM; Baklanova NA; Belenkov IuN
Kardiologiia; 2008; 48(2):52-64. PubMed ID: 18261010
[TBL] [Abstract][Full Text] [Related]
7. BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction.
Falcão LM; Pinto F; Ravara L; van Zwieten PA
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):121-9. PubMed ID: 15526247
[TBL] [Abstract][Full Text] [Related]
8. The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure.
van de Ven LL; van Veldhuisen DJ; Goulder M; Zilahi Z; Meyer WR; Willenheimer R
Int J Cardiol; 2010 Sep; 144(1):59-63. PubMed ID: 19481278
[TBL] [Abstract][Full Text] [Related]
9. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Latini R; Masson S; Anand I; Judd D; Maggioni AP; Chiang YT; Bevilacqua M; Salio M; Cardano P; Dunselman PH; Holwerda NJ; Tognoni G; Cohn JN;
Circulation; 2002 Nov; 106(19):2454-8. PubMed ID: 12417542
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Cohn JN; Tognoni G;
N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
[TBL] [Abstract][Full Text] [Related]
11. [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
Wang F; Xu ZM; Wang L; Bian WY; Jia X; Duan B; Li W; Li YS
Zhonghua Nei Ke Za Zhi; 2005 Jul; 44(7):490-4. PubMed ID: 16080835
[TBL] [Abstract][Full Text] [Related]
12. Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Yasumura Y; Miyatake K; Okamoto H; Miyauchi T; Kawana M; Tsutamoto T; Kitakaze M; Matsubara H; Takaoka H; Anzai T; Himeno H; Yokoyama H; Yokoya K; Shintani U; Hashimoto K; Koretsune Y; Nakamura Y; Imai K; Maruyama S; Masaoka Y; Sekiya M; Shiraki T; Shinohara H; Ozono K; Matsuoka T; Miyao Y; Nomura F
Circ J; 2004 Apr; 68(4):361-6. PubMed ID: 15056835
[TBL] [Abstract][Full Text] [Related]
13. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2003 Jun; 44(6):884-90. PubMed ID: 12791814
[TBL] [Abstract][Full Text] [Related]
14. [Clinical, hemodynamic and neurohumoral effects of long-term therapy of patients with severe chronic heart failure with beta-adrenoblocker bisoprolol].
Belenkov IuN; Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Narusov OIu; Baklanova NA; Masenko VP
Kardiologiia; 2003; 43(10):10-21. PubMed ID: 14593351
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.
Kasama S; Toyama T; Hatori T; Sumino H; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
Heart; 2006 May; 92(5):625-30. PubMed ID: 16159967
[TBL] [Abstract][Full Text] [Related]
16. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
Wong M; Staszewsky L; Latini R; Barlera S; Volpi A; Chiang YT; Benza RL; Gottlieb SO; Kleemann TD; Rosconi F; Vandervoort PM; Cohn JN;
J Am Coll Cardiol; 2002 Sep; 40(5):970-5. PubMed ID: 12225725
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies.
Bhatia V; Bhatia R; Mathew B
Cardiol Rev; 2005; 13(6):297-303. PubMed ID: 16230887
[TBL] [Abstract][Full Text] [Related]
18. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
19. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction.
Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Am Coll Cardiol; 2005 Mar; 45(5):661-7. PubMed ID: 15734608
[TBL] [Abstract][Full Text] [Related]
20. Valsartan for the treatment of heart failure.
Latini R; Masson S; Staszewsky L; Maggioni AP
Expert Opin Pharmacother; 2004 Jan; 5(1):181-93. PubMed ID: 14680446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
